Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Clinical trial NCT00418496 · COMPLETED
Trial details
- NCT number
- NCT00418496
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2006-11-08
- Primary completion
- 2013-02-28
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.